Leukemia inhibitory factor is synthesized and released by human eosinophils and modulates activation state and chemotaxis

Citation
Xy. Zheng et al., Leukemia inhibitory factor is synthesized and released by human eosinophils and modulates activation state and chemotaxis, J ALLERG CL, 104(1), 1999, pp. 136-144
Citations number
44
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
ISSN journal
00916749 → ACNP
Volume
104
Issue
1
Year of publication
1999
Pages
136 - 144
Database
ISI
SICI code
0091-6749(199907)104:1<136:LIFISA>2.0.ZU;2-Z
Abstract
Background: The cytokine leukemia inhibitory factor (LIF) is known to be pr oduced by both inflamed peripheral autonomic nerves and several cell types involved in the regulation of the immune response, We have recently demonst rated that several structural cell types in human airways produce LIF in re sponse to inflammatory stimuli and that LIF augments contractile responses to tachykinins in airway explants. Because the eosinophil is a major effect or cell in asthma and often found adjacent to the nerves, we hypothesized t hat eosinophils produce LIF and that LIF primes and upregulates eosinophil recruitment and function, allowing bidirectional neuroimmune interactions a nd augmentation of eosinophil-mediated injury. Objective: The purpose of this study was to demonstrate that human eosinoph ils synthesize and release LIF, to determine the effects of LIF on eosinoph il functions (ie, chemotaxis, granule protein release, expression of the ac tivation marker CD69, and apoptosis), and to compare serum LIF levels betwe en atopic and nonatopic individuals, Methods: Reverse-transcription PCR, ELISA, immunocytochemistry, chemotaxis assay, and flow cytometry were used, Results: Peripheral blood eosinophils express LIF and messenger RNA for LIF and LIF receptor, Serum LIF levels were higher in atopic patients with mil d asthma than in nonatopic normal donors. Eosinophils from nonatopic donors were stimulated by calcium ionophore to release small amounts of LIF (from almost none to 5.3 +/- 1.8 pg/10(6) cells), Eosinophils from atopic donors showed a 10-fold increase (from 45.1 +/- 38.7 pg/10(6) cells to 414.5 +/- 189.9 pg/10(6) cells), Preincubation of eosinophils with LIF increased eosi nophil peroxidase release 4-fold. LIF was not chemotactic for eosinophils b ut augmented chemotaxis mediated by substance P by 82% and by platelet-acti vating factor by 31%. LIF did not effect eosinophil apoptosis but increased CD69 expression. Conclusion: LIF has proinflammatory roles in eosinophil-dependent airway di sorders.